Kyowa Hakko Kogyo Co., Ltd.

Abbott Laboratories Corporation

Kyowa Hakko Kogyo Kabushiki Kaisha

Takao Iida

Kunikatsu Shirahata

Takashi Nara

Ryo Okachi

Shinzo Ishii

Hiroshi Kase

Masahiro Sugimoto

Koji Yamada

Hirofumi Nakano

Makoto Morimoto

Masaji Kasai

Tatsuya Tamaoki

Katsuichi Shuto

Shigeto Kitamura

Isami Takahashi

Kozo Asano

Hiroshi Sano

Mitsuru Takahashi

Chikara Murakata

Shiro Akinaga

Katsuhiko Ando

Hiromitsu Saito

Isao Kawamoto

Eiji Kobayashi

Yoshiharu Yokoo

Yuzuru Matsuda

Fusao Tomita

Toshikazu Kamiya

Tomoya Takahashi

Shinkichi Honda

Keiichi Takahashi

Mayumi Yoshida

Mitsunobu Hara

Noriaki Hirayama

Kazuhisa Fujimoto

Isao Matsubara

Hiromasa Kato

Yoichiro Arai

Kenji Omori

Isao Maisubara

Kazuyuki Iwahashi

Kazuko Hashizume

Kenji Torii

N-acylglutamine derivatives and cosmetic compositions

A hydroxamic acid compound represented by the general formula (I) or a salt thereof; ##STR1## wherein R.sup.1 represents a hydrogen atom, or a substituted or unsubstituted alkanoyl group, R.sup.2 represents an unsubstituted alkanoyl, substituted lower alkanoyl or substituted lower alkyl group, and m represents an integer of 3 to 7, which are useful for the prevention and/or treatment of diseases caused by lipoxygenase-mediated metablites.

Hydroxamic acid derivatives and use thereof in combatting

A novel compound, DC-107, is produced by culturing a microorganism belonging to the genus Streptomyces. It is useful as a medicine because of its antibacterial and anti-tumor activity.

Compound DC-107 produced by Streptomyces sp.

UCN-1028A and UCN-1028C having an anti-tumor activity and a protein kinase C inhibitory activity are produced by culturing a microorganism belonging to the genus Cladosporium.

UCN-1028A and UCN-1028C and process for the production thereof

A preventive and healing composition for diseases due to lipoxygenase metabolic products, which comprises an effective amount of a compound represented by the formula: ##STR1## wherein R is an alkyl group having 1 to 15 carbon atoms and at least one pharmaceutically acceptable carrier.

Preventive and healing composition for diseases due to lipoxygenase

A novel physiologically active substance K-252 having an antiallergic action is produced by culturing a microorganism of the genus Nocardiopsis.

Physiologically active substance K-252, process for producing same and

New substances designated as DC-45-A, DC-45-B.sub.1 and DC-45-B.sub.2 and represented by the following general formula: ##STR1## wherein (i) R.sub.1 and R.sub.2 together with the carbon atom therebetween represent the group ##STR2## and R.sub.3 represents ##STR3## (designated DC-45-A); (ii) R.sub.1 represents --OH, R.sub.2 represents --CH.sub.2 OH and R.sub.3 represents ##STR4## (designated DC-45-B.sub.1); or (iii) R.sub.1 and R.sub.2 together with the carbon atom therebetween represent the group ##STR5## and R.sub.3 represents ##STR6## (designated DC-45-B.sub.2). DC-45-A, DC-45-B.sub.1 and DC-45-B.sub.2 possess antibiotic and anti-tumor activity and may be obtained by culturing a microorganism of the genus Streptomyces. Preferred strain is Streptomyces bottropensis (FERM-P No. 5219; NRRL 12051).

Antibiotic substances DC-45, and their use as medicaments

New antibacterial compounds, DC--45--A.sub.1 and DC--45--A.sub.2 are produced by fermentation of a microorganism belonging to the genus Streptomyces. The antibiotics are accumulated in the culture liquor and are isolated therefrom. These compounds are also prepared by acid hydrolysis of known compounds, DC--45--A or DC--45--B.sub.2. DC--45--A.sub.2 is also prepared by acid hydrolysis of DC--45--A.sub.1.

Compounds having antibiotic activity, processes for their preparation,

New antibacterial compounds, XK-62-3 and XK-62-4, are produced by fermentation of microorganisms belonging to the genus Micromonospora. The compounds are accumulated in the culture liquor and are isolated therefrom.

Antibiotics XK-62-3 and XK-62-4 and process for production thereof

New antibiotic compounds, Fortimicin factors D and KE are produced by fermentation of microorganisms belonging to the genus Micromonospora. The antibiotic compounds are accumulated in the culture liquor and are isolated therefrom. A semisynthetic method of producing Fortimicin KE utilizing Fortimicin D is also disclosed.

Fortimicin factors D and KE compounds

New antibiotic compounds, Fortimicin factors KF and KG are produced by fermentation of microorganisms belonging to the genus Micromonospora. The antibiotic compounds are accumulated in the culture liquor and are isolated therefrom.

Fortimicin factors KF and KG and process for production thereof

Process for producing fortimicin factors

Growing community of inventors

Tokyo, Japan

Takao Iida